Physician profile
Gregory Tice
NPI 1700344488
$2,433.28
in general payments reported to CMS, 2019-2025
21 companies · $529 in 2025
The $529 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $133 · 2022: $373 · 2023: $576 · 2024: $822 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,877 · Education: $50.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,876.59 |
| Education | $50.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $600.68 | 2021-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $411.42 | 2022-2025 | Farxiga, Wainua, Brilinta |
| Philips North America LLC | $300.00 | 2023-2025 | (5091) Amb Mon & Diag Und, (Cm9) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $242.93 | 2021-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $222.08 | 2021-2025 | |
| Novo Nordisk INC | $81.06 | 2024-2025 | Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $75.85 | 2022-2024 | Camzyos |
| Scpharmaceuticals INC. | $75.73 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.05 | 2022-2025 | Jardiance |
| Boston Scientific Corporation | $52.31 | 2022-2024 | Watchman Access System |
| Amgen INC. | $48.64 | 2023-2025 | Repatha, Repatha |
| Medtronic, INC. | $44.69 | 2022-2023 | |
| Kiniksa Pharmaceuticals International, Plc | $36.78 | 2024 | Arcalyst |
| Pfizer INC. | $35.91 | 2021-2024 | |
| Inspire Medical Systems, INC. | $33.18 | 2025 | Inspire |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $24.75 | 2024 | Inpefa |
| Esperion Therapeutics, INC. | $20.52 | 2024 | Nexletol |
| Glaxosmithkline, LLC. | $19.78 | 2025 | Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $16.83 | 2022 | |
| Atricure, INC. | $16.23 | 2022 | |
| Amarin Pharma, INC. | $14.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Tice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.